Immunocore Holdings plc American Depositary Shares IMCR
i
Market dataready · fetched 2026-11-12T03:19:13.532Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:01.554630788Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T03:14:02.890860+00:00
Immunocore Holdings plc American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 42.92 | 199.2% | 39.4% | 23.30 | 342.4% | 34.1% |
| 25Δ | 41.96 | 218.9% | 37.7% | 25.80 | 276.2% | 26.2% |
| 30Δ | 40.99 | 238.7% | 35.9% | 27.59 | 230.9% | 20.6% |
| 35Δ | 40.03 | 258.4% | 34.2% | 29.38 | 185.6% | 14.9% |
| 40Δ | 36.64 | 212.5% | 23.5% | 30.32 | 162.4% | 12.2% |
| 45Δ | 34.48 | 179.4% | 16.8% | 30.80 | 151.0% | 10.9% |
| 50Δ | 33.49 | 159.6% | 13.8% | 31.28 | 139.5% | 9.7% |
| 55Δ | 32.50 | 139.8% | 10.8% | 31.76 | 128.0% | 8.5% |
| 60Δ | 31.51 | 120.0% | 7.8% | 32.24 | 116.6% | 7.3% |
| 65Δ | 30.52 | 100.2% | 4.9% | 32.72 | 105.1% | 6.1% |
| 70Δ | 29.58 | 89.8% | 3.1% | 33.20 | 93.6% | 4.9% |
| 75Δ | 28.70 | 89.8% | 2.5% | 33.68 | 82.2% | 3.6% |
| 80Δ | 27.82 | 89.8% | 2.0% | 34.16 | 70.7% | 2.4% |
20Δ
- Pseudo strike
- 42.92
- IV
- 199.2%
- B/E move
- 39.4%
- Pseudo strike
- 23.30
- IV
- 342.4%
- B/E move
- 34.1%
25Δ
- Pseudo strike
- 41.96
- IV
- 218.9%
- B/E move
- 37.7%
- Pseudo strike
- 25.80
- IV
- 276.2%
- B/E move
- 26.2%
30Δ
- Pseudo strike
- 40.99
- IV
- 238.7%
- B/E move
- 35.9%
- Pseudo strike
- 27.59
- IV
- 230.9%
- B/E move
- 20.6%
35Δ
- Pseudo strike
- 40.03
- IV
- 258.4%
- B/E move
- 34.2%
- Pseudo strike
- 29.38
- IV
- 185.6%
- B/E move
- 14.9%
40Δ
- Pseudo strike
- 36.64
- IV
- 212.5%
- B/E move
- 23.5%
- Pseudo strike
- 30.32
- IV
- 162.4%
- B/E move
- 12.2%
45Δ
- Pseudo strike
- 34.48
- IV
- 179.4%
- B/E move
- 16.8%
- Pseudo strike
- 30.80
- IV
- 151.0%
- B/E move
- 10.9%
50Δ
- Pseudo strike
- 33.49
- IV
- 159.6%
- B/E move
- 13.8%
- Pseudo strike
- 31.28
- IV
- 139.5%
- B/E move
- 9.7%
55Δ
- Pseudo strike
- 32.50
- IV
- 139.8%
- B/E move
- 10.8%
- Pseudo strike
- 31.76
- IV
- 128.0%
- B/E move
- 8.5%
60Δ
- Pseudo strike
- 31.51
- IV
- 120.0%
- B/E move
- 7.8%
- Pseudo strike
- 32.24
- IV
- 116.6%
- B/E move
- 7.3%
65Δ
- Pseudo strike
- 30.52
- IV
- 100.2%
- B/E move
- 4.9%
- Pseudo strike
- 32.72
- IV
- 105.1%
- B/E move
- 6.1%
70Δ
- Pseudo strike
- 29.58
- IV
- 89.8%
- B/E move
- 3.1%
- Pseudo strike
- 33.20
- IV
- 93.6%
- B/E move
- 4.9%
75Δ
- Pseudo strike
- 28.70
- IV
- 89.8%
- B/E move
- 2.5%
- Pseudo strike
- 33.68
- IV
- 82.2%
- B/E move
- 3.6%
80Δ
- Pseudo strike
- 27.82
- IV
- 89.8%
- B/E move
- 2.0%
- Pseudo strike
- 34.16
- IV
- 70.7%
- B/E move
- 2.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 71.90% | |
| 69.95% | |
| 64.87% | |
| 64.33% | |
| 60.45% | |
| 62.68% | |
| 65.13% | |
| 68.96% | |
| 76.66% | |
| 67.23% | |
| 71.79% | |
| 76.95% | |
| 70.83% | |
| 64.83% | |
| 66.91% | |
| 81.90% | |
| 80.96% | |
| 70.07% | |
| 72.93% | |
| 71.67% | |
| 66.84% | |
| 64.65% | |
| 65.12% | |
| 66.09% | |
| 67.59% | |
| 68.15% | |
| 62.53% | |
| 64.76% | |
| 70.87% | |
| 71.21% |
Biotechnology
IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United…
More →IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania.
More →IMRX
Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its proprietary drug…
More →IMTX
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in…
More →IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory…
More →IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York,…
More →